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Allergy represents a significant and increasing health problem worldwide. Allergic
symptoms have a negative impact on patients’ lives and societal economy.
Allergy immunotherapy should be included in optimal treatment strategies.
Allergy immunotherapy: the future of
allergy treatment
Jørgen Nedergaard Larsen , Louise Broge and Henrik Jacobi
ALK A/S, Bøge Alle´ 1, DK-2970 Hørsholm, Denmark
Allergic respiratory disease represents a significant and expanding health
problem worldwide. Allergic symptoms, such as asthma and hay fever,
cause sleep impairment and reduce school and work performance. The cost
to society is substantial. Allergen avoidance and pharmacotherapy cannot
control the disease. Only allergy immunotherapy has disease-modifying
potential and should be included in optimal treatment strategies. Allergy
immunotherapy was first administered as subcutaneous injections and has
been practiced for the past 100 years or so. Recently, tablet-based
sublingual allergy immunotherapy (SLIT) was introduced with
comprehensive clinical documentation. SLIT tablets represent a more
patient-friendly concept because they can be used for self-treatment at
home.
Introduction
Respiratory allergic disease represents a significant health problem in both developed and
developing countries [1]. During the past four decades, a dramatic increase in the prevalence
of allergic disease has occurred, and respiratory allergic disease is now the most common chronic
disease among adolescents and young adults [2,3]. The increase is especially problematic in
children because of the prognosis of chronic and frequently aggravating disease [4].
The clinical manifestations of allergic disease include: asthma; rhinitis; conjunctivitis; ana-
phylaxis; drug-, food-, and insect allergy; eczema; urticaria (hives); and angioedema. Respiratory
manifestations are the most prevalent, affecting up to 30% of the general population [4].
According to statistics from the World Health Organization (WHO), hundreds of millions of
people in the world have rhinitis and it is estimated that 235 million people have asthma (http://
www.who.int/mediacentre/factsheets/fs307/en/index.html). Asthma is a chronic inflammatory
disorder of the airways associated with airway hyper-responsiveness and airflow obstruction
(http://www.ginasthma.org/). Allergic rhinitis implies a blocked or runny nose, sneezing, and
itching secondary to immunoglobulin (Ig)-E-mediated inflammation of the nasal mucosa [5].
Rhinitis often occurs in combination with conjunctivitis, an inflammatory disease of the eye
characterized by flushing, swelling, itching, and watering of the eyes. Asthma and rhinocon-
junctivitis are linked by epidemiological, physiological, and pathological characteristics. The
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Allergen a molecule that is foreign to the human body and
capable of inducing an immune response in humans,
characterized by the presence of allergen-specific IgE
antibodies.
Allergy immunotherapy the administration of allergen (i.e.,
epitopes) for the purpose of inducing allergen-specific
immunological tolerance to treat allergic disease. It is a joint
designation covering allergen and nonallergen
immunotherapy [94].
Epitope an integral part of a molecule capable of interaction
with specific receptors, IgE antibodies, or T cell receptors, of
the adapted immune response.
Pharmacotherapy the administration of a chemically
synthesized pharmaceutical product to treat allergic disease.
It is symptom-relieving therapy without the induction of
allergen-specific tolerance.
SCIT subcutaneous immunotherapy [94].
Sensitization priming of the immune system that also
involves the generation of immunological memory. It is
antigen specific and essentially irreversible. B and T cells
proliferate and generate antigen-specific IgE antibodies and
T cells. Sensitization is the first step in the development of
allergy.
SLIT sublingual immunotherapy [94].
SLIT-drop sublingual immunotherapy using a liquid
formulation.
SLIT-tablet sublingual immunotherapy using a solid
formulation.
Subcutaneous under the skin. Vaccines are often delivered
by hypodermic injection into the subcutaneous tissue
located immediately beneath the skin.
Sublingual under the tongue. Medicine can be administered
sublingually on the mucosal surface in the hollow under the
tongue.
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mon aeroallergens is the strongest predicting factor for the devel-
opment of rhinoconjunctivitis as well as asthma [1].
It is becoming increasingly clear that allergy is a systemic immu-
nological disease initiated by the priming of an adaptive immune
response to common allergens (see Glossary) [6] (Fig. 1). Regardless
of the affected organ, allergic respiratory disease is characterized by
the presence of allergen-specific IgE antibodies and eosinophilic
inflammation. The allergic reaction is biphasic, with an immediate
reaction occurring within minutes following allergen exposure and
a late-phase reaction occurring hours later [6]. The immediate
reaction is caused by release of preformed mediators from basophils
and mast cells upon cross-linking of IgE bound to high-affinity
receptors on the cell surface. The late-phase allergic reaction is
caused by mobilization and attraction of inflammatory cells, such
as eosinophils, basophils, neutrophils, and mononuclear cells [6].
Current clinical guidelines recommend a combination of pa-
tient education, allergen avoidance, pharmacotherapy, and aller-
gy immunotherapy for treatment [5]. Allergen avoidance is
indicated whenever feasible, although, in practice, adequate
symptom control is difficult to achieve with allergen avoidance
alone. Although safe and inexpensive drugs are available for the
treatment of allergic symptoms, many patients report insufficient
symptom control. Importantly, pharmacotherapy has no effect onthe progression of the disease and treatment has to be adminis-
tered repeatedly as long as symptoms prevail, which often means
life-long.
Allergy immunotherapy is a causal treatment targeting the un-
derlying allergic disease, affecting basic immunological mecha-
nisms and resulting in the induction of immunological tolerance
[7]. Induced tolerance implies disease modification, the clinical
effects of which are sustained symptom relief after completed
treatment and/or prevention of disease progression. The latter
includes impeded aggravation of existing symptoms, preventing
the development of asthma in children with allergic rhinoconjunc-
tivitis and, potentially, also preventing supervening new allergies.
The capacity to alter the natural course of the disease differ-
entiates allergy immunotherapy from other treatment modalities.
Therefore, spending time, effort, and money on immunotherapy
represents an investment that will return sustained benefits from
improved prognosis and a relieved burden of disease. The clinical
effects during ongoing treatment are firmly established; the future
aim for allergy immunotherapy is to expand the evidence base
concerning the benefits of disease modification. Here, we provide
an update within the area of allergy immunotherapy, with partic-
ular focus on current state-of-the-art and the evidence base already
established.
Allergic disease
Allergy is a widespread disease with increasing prevalence
The prevalence of allergic disease is increasing [3]. At the begin-
ning of the 20th century, allergy was viewed as a rare disease.
Today, the most common manifestation of allergic disease is
rhinoconjunctivitis, affecting some 45% of young adults in select-
ed countries [3]. In Europe, a large study based on telephone
interviews among the general population reported prevalences
of allergic rhinoconjunctivitis of between 17% in Italy and 29%
in Belgium, with an overall average of 23% [8], in good agreement
with results from the European Community Respiratory Health
Survey [9]. The European Academy of Allergy and Clinical Immu-
nology predicts that, within the next few decades, more than half
of the European population will have some type of allergy [3].
Allergy is a chronic disease
The prevalence of allergic disease is higher among young patients
compared with older age groups [10]. This feature has incorrectly
been interpreted as a sign of patients outgrowing their allergy. The
Copenhagen Allergy Study is a repeated cross-sectional study of
the general population [10]. Analyzing the same study group
repeatedly showed an increase in prevalence of allergic disease
in the younger age groups and no change in the older age groups,
in agreement with a model in which the increase in prevalence
began to gather pace at a certain time point around the 1960s
[10,11]. Although some patients with allergy do experience a
relative mitigation in symptoms with age, after eight years more
than 85% were still symptomatic and 98% continuously had
objective signs of allergic sensitization [12]. These data classify
allergy as a chronic disease.
Allergy is a disease with many expressions
The most prevalent manifestation of allergy is respiratory
allergic disease, a common designation for the related symptoms,www.drugdiscoverytoday.com 27
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Routes of
exposure
 Allergic
manifestations
• Conjunctivitis
• Rhinitis
• Asthma
• Urticaria
• Atopic dermatitis
• Angioedema
• Anaphylaxis
Inhalation
Ingestion
Injection
• Pollen
• House dust mites
• Moulds
• Animal danders
Itching, watering, and blushing
of the eye
Itch in nose and palate
Sneezing and runny nose
Stuffed nose
Cough, wheezing, and short-
ness of breath
Itching red rash in upper layer
of skin
Hives
Dry skin eruption with itch
Swelling of skin or mucosal
membrane
Itching or pain
Allergic shock accompanied
by drop in blood pressure
Life-threatening if not treated
promptly and appropriately
• Bee venom
• Wasp venom
• Fire ant venom
• Plants
• Pollens
• Food
• Latex
• Food (e.g., milk,
egg, fish, nuts,
shellfish, etc.)
• Penicillin
Skin contact
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FIGURE 1
Allergy is a systemic disease in the immune system. Sensitization can occur following allergen exposure in the airways by inhalation, in the gastrointestinal tract by
ingestion, in body fluids by insect sting or in the skin by physical contact. Regardless of the route of exposure, symptoms can manifest in one or more tissues; for
example, in the eyes (conjunctivitis), nose (rhinitis), lungs (asthma), skin, either as a rash (urticaria), inflammation (atopic dermatitis), or swelling (angioedema), or
in the whole body accompanied by a drop in blood pressure (anaphylaxis).
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disease is caused by inhalation of organic dust, which is airborne
particles containing allergen molecules. The particles land on the
moist surface of the airway mucosa and the allergen molecules are
extracted and presented to the immune system. Allergen molecules
can be encountered by other routes, such as with a food allergy or
allergy to the venom of stinging insects, but the basic immunologi-
cal mechanisms are the same. Typical symptoms can vary according
to the route of exposure, but manifest either in the nose, eyes, lungs,
skin or gastrointestinal tract. Most patients have symptoms from
multiple organs simultaneously and the expression of allergic dis-
ease can change over time. These observations point to a model
where allergy is a systemic priming of the immune system with
subsequent dynamic manifestations of symptoms in multiple
organs (Fig. 1).
‘The Allergic March’
‘The Allergic March’ was a term coined to reflect the common
progression of disease starting in infancy as eczema and food28 www.drugdiscoverytoday.comallergy [13,14]. By the age three years, many children experience
spontaneous remission, but with increased risk of acquiring respi-
ratory allergic disease later in childhood or adolescence [15].
Furthermore, children with rhinoconjunctivitis have a high risk
of developing concomitant asthma. By the age of seven years,
asthma is three times more common among children with allergic
rhinoconjunctivitis compared with children without rhinocon-
junctivitis [16]. All sensitized individuals are likely to develop new
allergies. Thus, in the Copenhagen Allergy Study, the risk of
developing new IgE sensitization during an eight-year period
was three times higher among patients who were already sensi-
tized compared with patients without previous sensitization, and
the risk increased further with the number of allergies at baseline
[17].
Allergy is a disease of the immune system
The hallmarks of allergic disease (i.e., specificity and memory) are
profound features of the immune system, and recent consensus
on disease mechanisms in allergy is concerned with cells and
Drug Discovery Today  Volume 21, Number 1  January 2016 REVIEWS
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disease in the immune system and disease manifestations are not
limited to specific organs over time, as reflected in the allergic
march. For instance, most patients with allergic asthma also have
rhinoconjunctivitis [19]. The causal relation between systemic
sensitization and allergic symptoms from different organs received
broad recognition when the WHO endorsed the Allergic Rhinitis
and its Impact on Asthma (ARIA) initiative [6].
Allergic symptoms are difficult to control with pharmacotherapy
Many patients with allergy receive treatment with pharmacother-
apy, such as antihistamines and nasal corticosteroids for rhino-
conjunctivitis [5] and bronchodilators and inhaled corticosteroids
for asthma (http://www.ginasthma.org/). Such medication has
been shown in controlled trials to be effective in reducing symp-
toms, but do not address the underlying allergy and do not
prevent disease progression [20]. Furthermore, 57% of patients
report troublesome symptoms and describe symptom control as
being poor despite the fact that their symptomatic treatment is
guided by a physician [21,22]. Sixty-nine percent of patients are
restricted in their daily life [19]. These observations indicate that
pharmacotherapy alone is insufficient to control symptoms in
all patients.
Allergy is a severe disease in some patients
Disease severity refers to the reduced function of the organs
induced by the disease process or to the occurrence of severe acute
exacerbations [23]. Comorbidities add to the complexity of defin-
ing disease severity. The symptom severity of allergic disease varies
from mild to severe and from intermittent to persistent, whereas
exacerbations can occur in any patient regardless of severity [23].
Acute severe reactions include anaphylaxis, which is life threaten-
ing if not treated promptly and appropriately. Rhinoconjunctivitis
can be classified using a simple system comprising four categories
based on duration and symptom severity [5,6]. A French study
found 11% of patients consulting a primary-care physician to have
mild intermittent disease; 8% mild persistent; 35% moderate-to-
severe intermittent; and 46% moderate-to-severe persistent [24].
The moderate-to-severe group of patients according to this classi-
fication was large and heterogeneous, and attempts to improve the
usefulness of the classification for guidance of treatment are aim-
ing to include measures of disease control [25]. Of those patients
with rhinitis, 10–40% also have asthma [5].
Allergy significantly affects quality of life
Patients with allergy experience symptoms only when exposed to
the offending allergen, but allergen exposure cannot be complete-
ly avoided. Many patients do not receive an allergen-specific
diagnosis [19] and, therefore, patient education is not optimal.
Patients with allergy try to adapt their behavior to avoid allergen
exposure and symptoms, but this is a tedious process that is often
not possible. Living with residual symptoms has a significant effect
on allergic patients’ quality of life, including physical functioning,
energy, social functioning, general health perception, mental
health, and pain [26]. Patients with allergy experience limitations
in their daily life attributable to physical and emotional distur-
bances [26], and twice the number of patients with allergic rhi-
noconjunctivitis compared with controls, are affected by sleepdisturbance [27]. Of patients with allergic rhinoconjunctivitis,
79% are impaired in their professional life [28].
Allergy is a significant burden to society
The burden of allergic disease to society is distinct in two aspects:
first, patients with allergy use resources when utilizing the health-
care system. In pharma-economic terms, these costs are the direct
costs, and include emergency room visits, visits to outpatient
clinics, and medicinal costs [29]. A certain percentage of these
patients have severe symptoms, representing a high cost in this
category [30]. The second aspect is associated with reduced perfor-
mance at work or in school, the so-called ‘indirect costs’ [31].
Patients in this category cause a large burden because of their high
numbers [28] (http://www.theipcrg.org/display/TreatP/2012/03/
28/New%3A+Respiratory+Allergies+book). Patients with moder-
ate allergic disease might not take many sick days per year, but
while present at work or school, they might still be affected by
symptoms and have a suboptimal performance. As noted above,
79% of patients with allergic rhinoconjunctivitis are impaired in
their professional life [28]. An American study showed allergic
rhinitis to be the most costly disease of all, from an employer
perspective [32].
Allergy immunotherapy
Background
The concept of allergy immunotherapy recently celebrated its 100-
year anniversary, based on the first scientific publication, in The
Lancet, by the British doctor Leonard Noon in 1911 [33]. Noon
described observations by subcutaneous inoculation of a pollen
extract into a few patients and, although allergen immunotherapy
in principle is conducted in a similar way today, major progress has
been made, in particular in three important areas: (i) the mecha-
nistic understanding of the mode of action; (ii) the quality of
vaccines; and (iii) the quality of clinical documentation.
Mechanistic mode of action
Allergy immunotherapy changes the response to allergen exposure
by inducing immunological tolerance [34]. A patient with allergy
has symptoms only when exposed to the relevant allergen. For
respiratory allergies, allergens arrive at the airway mucosa airborne
on particles present in the air breathed. Upon contact with the
moist surface of the mucosa, the allergen molecules are extracted
and come into contact with the immune system. Allergen is bound
by allergen-specific IgE antibodies, which leads to activation of
mast cells and basophils, and rapid release of histamine and other
mediators directly responsible for allergic symptoms. In addition,
allergen-specific T cells are activated, leading to an inflammatory
reaction (Fig. 2). The blood vessels dilate and leak plasma and cells
into the mucosal tissue. The inflammatory response activates mast
cells, basophils, eosinophils, neutrophils, and macrophages, and
attracts them to the airway mucosa, giving rise to bronchocon-
striction and mucus secretion. Eyes redden and flood with tears
and the nose sheds aqueous secretion. Itching in the nose, palate,
throat, and eyes is characteristic of the allergic response and
distinguishes allergic symptoms from those of infectious disease.
When allergen is taken up by natural exposure, the amount of
allergen presented to the immune system in the mucosa is rela-
tively low, but the result is efficient stimulation of the allergicwww.drugdiscoverytoday.com 29
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Allergen molecule carried by
inhaled particle to airway
mucosa
Allergen molecule carried by 
inhaled particle to airway
mucosa
1. A person can become sensitized
when exposed to for example grass
pollen. White blood cells activate and 
accumulate in airway mucosa.
Some of the white blood cells, B cells,
start to produce lgE antibodies to grass
pollen and release them into the blood.
2. Some lgE antibodies attach them-
selves to the surface of mast cells and
basophils, which are filled with grains 
containing allergic mediators.
1. As a consequence treatment, T cells
instruct some of the B cells to produce
IgG antibodies instead of IgE
antibodies.
2. IgG antibodies do not cause mast
cell degranulation, but bind to allergen
molecules, thereby blocking their
binding to IgE, preventing cross-linking
and release of allergic mediators.
3. Only a few allergen molecules are
available for IgE binding and the
allergic reaction is reduced or, in some
cases, even discontinued.
4. As another consequence of the
treatment, some T cells develop into
regulatory T cells, which reduce
antibody production in B cells, and
effectively secure a diminished allergic
immune response.
IgG
antibodies
attach to
allergen
molecules
IgE
antibodies
T cell
B cell
B cell
Immunological response
by an allergic person
Immunological response
after allergy immunotherapy
Regulatory
T cell
RIE JERICHOW
3. Repeated exposure to grass pollen
leads to an immediate reaction, which
is triggered by cross-linking of the
cell-bound IgE and results in rapid
release of allergic mediators.
4. Other white blood cells, T cells,
drive a delayed and prolonged inflam-
matory reaction peaking some 6–10 h
later with itching, swelling and excessive
secretions.
(a) (b)
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FIGURE 2
Immunological responses. (a) An allergic reaction is initiated when the immune system is unintentionally sensitized to a molecule that does not represent a threat
to the body. The immune system reacts by developing antibodies [e.g., immunoglobulin E (IgE) antibodies] and T cells that are specifically reactive with the
allergen molecules. The resulting interactions trigger allergic symptoms, such as allergic rhinitis and asthma. (b) The immunological response is modified by
allergy immunotherapy inducing immunological tolerance through induction of IgE-blocking IgG antibodies and regulatory T cells. This treatment can result in no,
fewer, or less severe allergic reactions.
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when allergen is administered as immunotherapy, the amount of
allergen is relatively high. One dose administered in immunother-
apy, either sublingually or subcutaneously, corresponds approxi-
mately to 100 times the estimated maximal yearly intake through
natural exposure [35]. The quantitative difference in combination
with the different route of entry into the body exerts a profound
effect on the immune system, which responds by inducing immu-
nological tolerance to the allergen. Two mechanisms are thought
to have a major role: immune deviation and induction of regula-
tory T cells [36].
Immune deviation is a term signifying a modified immunologi-
cal response to allergen exposure, where allergen-specific T helper
type 1 (Th1) cells are mobilized and stimulated at the expense of
Th2 cells. Th1 cells produce interferon gamma (IFN-g), stimulating
B cells to produce IgG instead of IgE, and IgG is not capable of
triggering an allergic reaction.
Regulatory T cells are a diverse group of T cells that are active in
the regulation of immune responses, and allergen-specific
CD4+CD25+ regulatory T cells have been demonstrated after aller-
gy immunotherapy [37]. They produce interleukin (IL)-10 and30 www.drugdiscoverytoday.comtransforming growth factor (TGF)-b, and have the potential to
suppress local Th2 cell responses and redirect antibody class
switching in favor of IgG4 (IL10 isotype switch factor), and IgA
(TGF-b isotype switch factor) (Fig. 2). Allergen-specific IgG4 anti-
bodies interrupt allergen presentation to Th2 cells and, in addi-
tion, block allergen-induced activation of mast cells and basophils,
thereby significantly weakening the allergic reaction.
The relative contributions from immune deviation and regula-
tory T cells are not established, but the end result is reduction and,
in some cases, even elimination of the capacity to mount an
allergic reaction in response to allergen exposure.
Treatment modalities
The original administration form of allergy immunotherapy was
by subcutaneous injection (SCIT). This treatment regimen is tra-
ditionally conducted in two phases: an initial up-dosing phase and
a subsequent maintenance phase. The up-dosing phase is an
individual titration, where increasing doses are administered for
the purpose of slowly building tolerance and carefully assessing
the sensitivity of the patient. The maximum-tolerated dose, or the
maximum dose recommended, whichever is reached first, is then
Drug Discovery Today  Volume 21, Number 1  January 2016 REVIEWS
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in the doctor’s surgery because there is a small risk of inducing
allergic reactions, which can become severe or even life threaten-
ing if not treated promptly and appropriately.
In Europe, products for SCIT are typically formulated with
aluminum hydroxide, which forms a complex with the active
protein ingredient, acting as a depot and releasing the allergens
slowly. Importantly, the allergen extract must be standardized to
achieve a reproducible composition and thereby facilitate a pre-
dictable outcome of the treatment. The European allergen pro-
ducts are distributed with recommendations for use and packaged
into treatment sets for individual patients. Only a few products are
approved by regulatory authorities and most are sold as named
patient products [38]. In the USA, allergen products for SCIT are
sold as aqueous bulk extract, which is then mixed and diluted for
the individual patient in the doctor’s surgery, and administered as
subcutaneous injections [7].
Other administration routes have been investigated, including
all mucosal surfaces; the most frequently used is sublingual ad-
ministration under the tongue. The treatment is given either as
drops or fast-dissolving tablets. The majority of the market for drop
products comprises named patient products, although sublingual
immunotherapy has only limited distribution in the USA.
Fast-dissolving tablets for sublingual immunotherapy have re-
cently been developed in comprehensive clinical trial programs
and, as such, they must be considered the only marketed allergy
immunotherapy products to meet current requirements for regu-
latory approval. Two European manufacturers (ALK, Denmark,
and Stallergenes, France) have initiated strategies to develop SLIT
tablets with the aim of authorization in major European markets
and further propagation to more continents. At present, two
products have received marketing authorizations in Europe and
three in the USA, and, for all products, the treatment regimen is
once-daily administration, with a safety profile that allows home
use.
Quality of immunotherapy products
Allergen products are used for allergen-specific management of
allergic disease. No structural feature defining an allergen has
hitherto been described and the definition of an allergen is based
solely upon the functional criterion of being able to elicit an IgE
response in susceptible individuals. Thus, the allergen is defined by
the immune system of the individual patient. Every patient has a
unique sensitization pattern with respect to molecules and epi-
topes. Based on this definition, any immunogenic protein (anti-
gen) has allergenic potential, even though most patients with
allergy have IgE antibodies specific for a relatively limited number
of ‘major’ allergens.
All marketed allergen products are manufactured by aqueous
extraction of allergenic source materials derived from natural raw
materials, such as pollens, house dust mite cultures, animal hair
and/or dander, or insect venoms. Natural raw materials are inher-
ently variable in composition and, therefore, standardization is of
major importance [39,40]. The standardization procedure includes
all aspects of the manufacturing procedure, from selection and
collection of raw materials, securing collector qualifications, ex-
tract preparation and storage, to validation of assays and reagents
[41].Control of the variation in the natural source material is han-
dled by use of references and control extracts. In Europe, each
manufacturer establishes their own in-house reference prepara-
tions (IHRP), which must be matched by each and every batch.
New batches are compared with the IHRP using a combination of
laboratory techniques to achieve a uniform composition with
regard to complexity of the extract, the content of major allergen,
and the IgE-binding potency. In the USA, the US Food and Drug
Administration (FDA) issues standards and assays to be used by all
manufacturers.
Different manufacturers use different raw materials, produc-
tion processes, and standardization procedures, and, therefore,
allergen products are not generic, but differ in their composition,
IgE-binding potency, and extent of quality control between
manufacturers. No international standards are in effect. This
means that products from different manufacturers can perform
differently in patients and, as a consequence, clinical results
cannot be extrapolated directly from one allergen product to
another [42].
Currently, different immunotherapy products with different
qualities of clinical documentation are available on the market
for the treatment of the same allergy. In such cases, selection of an
authorized product with the highest level of evidence would
optimize safety, efficacy, reproducibility, and, hence, predictabili-
ty of the treatment. Once a patient has been identified as eligible
for immunotherapy, the choice of either subcutaneous or sublin-
gual immunotherapy might rely on more practical patient pre-
ferences.
Clinical documentation
Since the first report of allergy immunotherapy appeared in the
literature some 100 years ago [33], many studies have reported the
efficacy of allergy immunotherapy in different allergies, seasonal
as well as perennial, and different indications, rhinoconjunctivitis
as well as asthma. However, many published trials are small and
the documentation is heterogeneous with respect to indications
and design. Some early trials were planned with an element of
exploration and they do not fulfill the International Conference
on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) criteria for a therapeutic
confirmatory trial (http://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.
pdf). In addition, products for allergy immunotherapy are not
generic, as discussed above, and results from trials with different
products cannot be taken as a demonstration of a class effect as
such. For these reasons, the interpretation of the clinical docu-
mentation for allergen immunotherapy requires caution [43].
More recently, SLIT tablets have been documented in
comprehensive clinical development programs designed to fulfill
regulatory requirements for market authorization and, currently,
SLIT tablets are the best-documented immunotherapy products.
Recent guidelines include recommendations for the treat-
ment of allergic rhinitis in concordance with the grades of
recommendation, assessment, development, and evaluation
principle focusing more critically on clinical relevance and cost
effectiveness [44]. To advance the quality of documentation, the
European Medicines Agency (EMA) has published guidelines for
product registration regarding production and quality issueswww.drugdiscoverytoday.com 31
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TABLE 1
The large SLIT-tablet immunotherapy studies
Characteristic of study Treatment Clinical trial identifier Refs
Grass pollen allergy
Phase II Grazax n.a., GT02 [56]
Oralair NCT00367640, VO34.04 [77]
Phase III Grazax NCT00227279, GT08 [74,80,95]
Oralair NCT00418379, VO53.06 [58]
Disease modification Grazax NCT00227279, GT08 [57]
USA Grastek NCT00421655, GT14 [96]
Grastek NCT00562159, P05238 [81]
Oralair NCT00955825, VO61.08 [82]
Children Grazax NCT00408616, GT12 [78]
Grastek NCT00550550, P05239 [83]
Oralair NCT00409409, VO52.06 [79,97]
Ragweed pollen allergy
USA Ragwitek NCT00783198, P05233 [84]
Ragwitek NCT00770315, P05234 [85]
House dust mite allergy
Under
development
NCT00674700, VO57.07 [98]
Under
development
NCT00389363, MT02 [99,100]
Note: GRAZAXW is the registered trade name for the SQ-grass SLIT tablet in Europe.
GRASTEKW is the registered trade name for the SQ-grass SLIT tablet in the USA. ORALAIRW
is the registered trade name for the 5-grass SLIT-tablet.
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Scientific_guideline/2009/09/WC500003333.pdf), and for the
clinical development of immunotherapy products (http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2009/09/WC500003607.pdf). Furthermore, the Mono-
graph on Allergen Products in the European Pharmacopoeia was
recently updated [45].
Subcutaneous immunotherapy
The WHO Position Paper on Immunotherapy [46] made recom-
mendations regarding composition and dosing for products
intended to be used for SCIT. Analysis of the published clinical data
through the Cochrane Collaboration provided scientific evaluation
and expanded the evidence base for subcutaneous immunotherapy
for both rhinoconjunctivitis [47] and asthma [48]. The ARIA docu-
ment [5], under the auspices of the WHO, assigned allergy immu-
notherapy the highest level of evidence (i.e., level Ia). As mentioned
above, the heterogeneity in the included studies was substantial and
potential publication bias could not be excluded. One large trial has
been performed in adult patients with grass pollen-induced allergic
rhinitis. Patients had moderately severe symptoms that were inade-
quately controlled with standard pharmacotherapy and the study
demonstrated reductions in symptom and medication use as well as
improvement in quality of life after one season of SCIT [49].
SLIT drops
Meta-analysis of grass pollen immunotherapy trials [50] show that
published SLIT-drop trials show greater heterogeneity compared
with SCIT trials, suggesting that some SLIT-drop products have
efficacy similar to SCIT, whereas others do not. The efficacy of SLIT
in general has been demonstrated in four meta-analyses for allergic
rhinoconjunctivitis and four meta-analyses for asthma, including
both children and adults [43]. One Cochrane review analyzed the
results and documented efficacy of SLIT drops in seasonal and
perennial rhinitis in both children and adults [51]. The ARIA
document [5] also assigned sublingual immunotherapy the high-
est level of evidence, although, as mentioned above, the hetero-
geneity in the included studies was substantial and each product
has to be evaluated separately by available data. One large trial has
been performed in adult patients with ragweed pollen-induced
allergic rhinoconjunctivitis; the study demonstrated reductions in
total combined symptom and medication scores [52].
SLIT tablets
SLIT tablets have been developed in comprehensive clinical devel-
opment programs designed to meet regulatory requirements for
marketing authorization in Europe. Currently, SLIT tablets are the
best-documented immunotherapy products on the market, and
the only products that are developed to meet current standards for
clinical documentation in both the USA and Europe. The studies
are large, randomized, double-blinded, controlled and confirma-
tory [43]. In parallel and partly because of the emergence of these
large studies, new European guidelines have been established
(http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500003607.pdf). So far, 14 large
studies based on SLIT tablets have been published (Table 1).
Allergy immunotherapy improves quality of life
Allergy is peculiar in that the burden of disease varies considerably
between times of exposure versus nonexposure to allergens. The
quality of life of patients with allergy deteriorates during exposure32 www.drugdiscoverytoday.comto the relevant allergen; however, immunotherapy diminishes the
reduction and thereby improves quality of life for these patients.
There is no consensus on how patient-reported outcomes should
be calculated and there is no validated standard for reporting health
impact for allergy immunotherapy. Most often used is the disease-
specific Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
developed to assess seven domains of the quality of life in symp-
tomatic patients during allergen exposure (e.g., during a pollen
season), allowing for assessment of a symptomatic baseline [53].
A minimal important difference for change in the actively treated
group of 0.5 has been proposed based on studies of pharmacothera-
py [54]; however, in clinical trials of seasonal allergen immunother-
apy, subjects are typically randomized during a preseasonal,
relatively asymptomatic period, and results reflect the difference
between groups treated with active treatment versus placebo. Eval-
uating symptoms in a previous season will not lead to valid baseline
values, because symptoms are dependent on exposure, which varies
from year to year [55]; however, baseline assessment might be
relevant for perennial allergies, such as allergy to house dust mites.
A minimal important difference appropriate to the design of clinical
trials of allergy immunotherapy, without a symptomatic baseline
and comparing treatment groups rather than change from baseline,
has not yet been established.
Three large trials of SLIT tablets demonstrated a statistically
significant improvement in quality of life among patients with
grass pollen allergic rhinoconjunctivitis during the pollen season
[56–58]. All studies used the disease-specific RQLQ instrument
[53]. In the long-term trial with the SQ grass SLIT tablet, the
highest effects were observed in the sleep and eye symptom
domains [59]. Impaired sleep exerts a particular effect on
patients’ well-being, as well as school and work performance,
and, therefore, has a major impact on quality of life. The benefi-
cial effect of immunotherapy was sustained for two years after the
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improvement in quality of life using subcutaneous  injection
immunotherapy [60]. All domain scores improved significantly
using the RQLQ instrument [53].
Allergy immunotherapy is cost effective
The societal cost of allergic disease is considerable, mainly because
of the high prevalence of allergic rhinoconjunctivitis and the
associated loss of productivity. A Swedish study estimated the cost
of lost productivity caused by rhinitis at EUR 2.7 billion per year in
Sweden [31], and an American study established rhinitis as the
most costly disease for American employers [32]. Allergy immu-
notherapy implies treatment over at least a three-year period, but
as the objective of the treatment is induction of immunological
tolerance, the effect might persist several years thereafter. This
aspect of disease modification has been demonstrated clinically for
only a few products [57,61]. Where such data are available, the
total healthcare cost of the treatment could be regarded as an
investment, with returns in the form of cost savings over the
following years because of disease modification [62–64].
Theoretically, the societal benefit of allergen immunotherapy is
associated with cost savings caused by decreased consumption of
pharmacological products, fewer visits to general practitioners and
specialists, as well as incurred productivity gains. In addition,
disease modification potentially leads to a reduced risk of devel-
oping asthma [65], which is of societal benefit because of the costs
associated with the more severe disease in patients with asthma
patients (http://www.theipcrg.org/display/TreatP/2012/03/28/
New%3A+Respiratory+Allergies+book).
Both SCIT and SLIT tablets are cost effective [66], with the latter
being so in both Northern [67] and Southern [68] European
countries.
State-of-the-art
Allergy immunotherapy tablets
As mentioned previously, fast-dissolving allergen immunotherapy
tablets for sublingual administration have been, and are currently
being, developed by the industry in comprehensive clinical devel-
opment programs designed to satisfy current requirements for
market authorization. The clinical development programs com-
prise Phase I safety and tolerability studies, large Phase II dose-
finding studies, and large Phase III efficacy and safety studies,
including studies in patients with rhinoconjunctivitis as well as
asthma, and studies in adults as well as in children. All studies are
randomized, double blinded and placebo controlled, and all
patients enrolled have free access to standardized rescue medica-
tion. The primary outcome of SLIT-tablet trials is based on symp-
tom and rescue medication scores recorded daily.
Currently, three products have been developed in accordance
with applicable regulatory requirements for marketing authoriza-
tion. The SQ grass SLIT tablet (ALK, Denmark) and a ragweed SLIT
tablet in the same formulation, and the 5-grass SLIT tablet (Stal-
lergenes, France). The SQ grass SLIT tablet is a fast-dissolving tablet
of a freeze-dried formulation containing grass pollen extract from
one grass species, Phleum pratense [69], whereas the 5-grass SLIT
tablet is a multiparticulate tablet produced by compression and
containing a mixture of pollen from five homologous grass species
with high IgE cross-reactivity [70].For the SQ grass SLIT tablet, simultaneous authorization in 27
European countries was based on Phase I–III studies comprising
almost 1800 patients [56,71–75]. A large dose-finding trial (N = 855
patients) established the optimal dose [56], which was then docu-
mented in a large safety and efficacy study (N = 634 patients) [57].
For the 5-grass SLIT tablet, the clinical development program
comprised Phase I, II, and III studies, including 1350 patients
[58,76,77]. A large dose-finding trial (N = 628 patients) established
the optimal dose, which was then documented in a large safety
and efficacy study (N = 633 patients) (Table 1).
During pre- and co-seasonal treatment for one grass pollen
season, similar clinical results were obtained with the SQ grass
SLIT tablet and the 5-grass SLIT tablet [56,77]. Likewise, similar
results were obtained in children for treatment in one season with
the two products [78,79] and for adults treated for three seasons
[58,80]. Studies performed in Europe [56,77] yielded results simi-
lar to those obtained in North America [81,82] for adults, and
also for pediatric patients using the SQ grass SLIT tablet [78,83]
(Table 1).
A SLIT tablet for the treatment of ragweed pollen allergy has also
been developed. Two large randomized, double-blinded placebo-
controlled trials have been published demonstrating clinical effi-
cacy in adult patients with ragweed pollen-induced rhinitis with or
without conjunctivitis [84,85].
The safety profile of the SLIT tablets support at-home use once
the first dose is tolerated when administered under physician
supervision. This procedure allows for not only possible treatment
of any immediate adverse effects in sensitive patients, but also
discussion of local adverse effects, such as mild itching and mild
swelling of the lips and floor of the mouth, which are common but
usually of short duration and, in most patients, cease to occur after
a few weeks of treatment.
Disease modification: post-treatment effect
The capacity of allergy immunotherapy to modify the natural
course of allergic disease was first discussed in by Noon in 1911.
He noted that patients who developed ‘active immunity’ against
the pollen toxin became ‘cured’ of their rhinoconjunctivitis symp-
toms. The long-term trial with the SQ grass SLIT tablet comprised
three years of daily treatment and a two-year follow-up period to
demonstrate disease modification through post-treatment effects
[57] (Fig. 3). There was a significant reduction in symptoms
compared with placebo during the treatment period, and this
reduction was maintained during follow-up; thus, the indication
‘disease-modifying treatment’ was approved by the European
authorities. The SQ grass SLIT tablet is the only immunotherapy
tablet so far with this approved indication.
The long-term confirmatory trial with the 5-grass SLIT tablet
comprised three years of pre- and co-seasonal treatment followed
by a two-year follow-up period to demonstrate disease modifica-
tion through post-treatment effect (ClinicalTrials.gov identifier:
NCT00418379) [86,87]. Although there was a statistical significant
difference between active and placebo at all time points [88,89],
‘disease modification’ is not in the label of this product.
Disease modification: prevention
Another element of disease modification is prevention, and pre-
ventive effects of allergy immunotherapy might be possible onwww.drugdiscoverytoday.com 33
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FIGURE 3
Long-term effect of the SQ grass SLIT-tablet showing a sustained effect of allergy immunotherapy two years after termination of three years of daily treatment
using a fast-dissolving tablet under the tongue. The tablet contained a standardized grass pollen extract in a freeze-dried formulation. All patients in the study had
access to standard pharmacotherapy as needed.
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Asthma (http://whqlibdoc.who.int/hq/2003/who_nmh_mnc_cra_
03.2.pdf) defines primary prevention as prevention of immuno-
logical sensitization (i.e., the development of IgE antibodies).
Secondary prevention is defined as preventing the development
of disease in sensitized individuals, especially preventing the
development of atopic eczema, rhinoconjunctivitis, and allergic
asthma. Tertiary prevention is defined as preventing an attack of
illness in patients with asthma and/or allergic diseases.
However, this definition does not take into account that im-
munotherapy might provide different types of secondary preven-
tion. For example, preventing asthma in children with
rhinoconjunctivitis can also be considered secondary prevention,
and this is also true for the prevention of new sensitizations in
individuals who are already sensitized to one allergen.TABLE 2
Proposed new prevention terminologya,b
Type of effect 
Primary prevention Prevention of first sensitization 
Secondary prevention Prevention of clinical symptoms in sensitized individu
Prevention of new sensitizations with clinical manifes
in patients with grass pollen allergy
Prevention of progression to new clinical manifestatio
with rhinoconjunctivitis
Treatment Improve control of symptoms 
a Allergy is a systemic disease of the immune system characterized by sensitization and the occu
and, consequently, all the preventive effects mentioned above are examples of disease modifi
individuals is also secondary prevention, although in practical terms this is normally conside
b, disease prophylaxis; , disease modification; 0, symptom relieving and/or controlling 
34 www.drugdiscoverytoday.comFurthermore, preventing attack of illness in patients with asth-
ma and/or allergic disease is referred to as tertiary prevention in the
WHO definition (http://whqlibdoc.who.int/hq/2003/who_nmh_
mnc_cra_03.2.pdf). However, whether this is at all prevention or
merely corresponds to a symptom-relieving and/or controlling
effect during treatment is unclear. For these reasons, we consider
the current terminology to be insufficient, and propose a more
specific and comprehensive terminology concerning prevention,
as outlined in Table 2.
The natural history of allergic disease starts with family dispo-
sition or genetic susceptibility. Genetic susceptibility is an inher-
ited predisposition to become allergic. However, before disease can
manifest, the immune system must be primed, an event referred to
as sensitization. During sensitization, the immune system is
primed for a specific allergic reaction, and cells and moleculesEffect during
ongoing treatment
Post-treatment
effect
 
als  
tations; e.g., birch pollen allergy  
ns; e.g., asthma in patients  
0 
rrence of allergen specific IgE. From this initial asymptomatic state, disease can propagate
cation. According to this definition, the prevention of first clinical symptoms in sensitized
red to be disease prophylaxis.
during treatment.
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FIGURE 4
Prevention of the development of asthma in children with allergic
rhinoconjunctivitis after three years of subcutaneous injection
immunotherapy. Only approximately half as many children in the
immunotherapy-treated group developed asthma compared with the
control group. Both groups of children had access to standard
pharmacotherapy as required.
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immunological memory is stored. In this sequence of events, two
levels of prevention are theoretically possible, that is, prevention
of sensitization in healthy individuals, and prevention of disease
in sensitized individuals.
Prevention of first sensitization (i.e., prevention of sensitization
in healthy individuals) is primary prevention, whereas preventing
clinically manifest disease in individuals with sensitization is
secondary prevention (Table 2). Both these levels of prevention
can be considered disease prophylaxis because allergic symptoms
have not yet occurred, although a preclinical disease state has been
initiated.
Having established sensitization with disease implies a high risk
of disease progression in two dimensions. First, one disease might
develop into two clinical manifestations (e.g. rhinoconjunctivitis
caused by a specific allergen might develop into rhinoconjuncti-
vitis with asthma caused by the same allergen). Second, one allergy
(e.g., to house dust mites) might develop into two allergies (e.g., to
house dust mites and grass pollen). According to our proposed
terminology, secondary prevention is further separated into pre-
vention of progression to new clinical manifestations, and pre-
vention of development of additional sensitizations and/or
allergies.
All these preventive effects can theoretically be characterized as
effects occurring during ongoing treatment or they can be post-
treatment effects when treatment has been terminated. Disease
modification also includes post-treatment control of symptoms,
because the immunological modification resulting from allergy
immunotherapy has resulted in a sustained reduction in the
response to allergen exposure.
Ongoing prevention studies
Studies of primary prevention are currently in progress. This is
prevention of the first allergic sensitization, and children are
consequently selected on the basis of family history, because
allergy among parents and/or siblings is a strong predictor of
allergy later in life. In the Mite Allergy Prevention Study (MAPS)
[90], 120 children five to six months of age at high risk of
developing allergy were treated with SLIT drops containing house
dust mite allergen extract twice daily for one year. The children are
being assessed regularly at three-month intervals for the appear-
ance of allergic sensitization by skin prick test. Given that asthma
is difficult to diagnose precisely at this age, a follow-up at five years
of age is planned to assess asthma development.
Another study, which preceded the MAPS study and showed
good tolerability, was the Global Prevention of Asthma in Chil-
dren (GPAC) study. However, the study was terminated after the
pilot phase [91], because no difference in treatment-allergen spe-
cific IgE/IgG antibodies or associated Th cell responses could be
detected between active and placebo groups at six months of
treatment. The reason why this requirement to proceed beyond
the pilot phase was included in the protocol was that infants could
not be trained to hold the liquid under the tongue for two minutes,
and thus there was a risk that the amount of allergen penetrating
through the mucosa would be under the threshold required for
triggering immunologic processes.
A few studies have looked at secondary prevention in the
form of asthma prevention in children with rhinoconjunctivitis.One randomized and controlled open trial was the PAT-trial,
where children with allergic rhinoconjunctivitis were followed
for ten years with asthma development as the primary outcome
[65] (Fig. 4). The children in the active group were initially
treated with immunotherapy for three years, and asthma inci-
dence was recorded at three, five, and ten years after initiation of
treatment. The intervention group showed a significant positive
odds ratio for reducing the risk for development of asthma at
the end of treatment after three years compared with the
control group. The difference was maintained at follow-up after
ten years.
A large ongoing asthma prevention trial, the (GAP) trial, is
designed to assess the preventive effect of the SQ grass SLIT tablet
on the development of asthma in children with allergic rhino-
conjunctivitis in a trial designed to comply with current regulatory
standards. In total, 812 children were enrolled in a randomized,
double-blinded, placebo-controlled multicenter study comprising
101 sites in 11 European countries [92]. The trial is designed with
three years of treatment and two years of follow-up.
Prevention of new sensitizations in sensitized individuals has
been reported in a few small studies [93], but data are currently not
available from large randomized, controlled studies.
Concluding remarks
The number of patients with allergies is on the increase worldwide,
and it appears that current healthcare measures to control this
disease are inadequate. The European Federation of Allergy and
Airways Diseases Patients’ Associations, EFA, has issued a call for
action to raise awareness and improve treatment of respiratory
allergy (http://www.theipcrg.org/display/TreatP/2012/03/28/
New%3A+Respiratory+Allergies+book). One of the action points
specifically highlights the unique property of allergy immunother-
apy to modify the course of respiratory allergy and requests
the European Union and Member States to improve access to
preventive and/or disease-modifying treatments. In addition,www.drugdiscoverytoday.com 35
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issued a European Declaration on Immunotherapy focusing on
allergy immunotherapy as the foundation for the battle against
allergy, a public health threat of pandemic proportions [3].
The unique aspect of allergy immunotherapy is the capacity
to modify the natural course of disease by inducing long-
term immunological tolerance; therefore, future directions for36 www.drugdiscoverytoday.comimmunotherapy should be concerned with providing evidence of
the different levels of disease-modifying effects, cf. Table 2.
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